ReutersNew rivals to top diabetes drug Lantus show promise in studiesReutersJune 14 (Reuters) – Diabetes patients stand to benefit from two experimental insulin therapies that could eventually replace Sanofi’s global leader Lantus, according to results from large clinical trials released on Saturday. Sanofi’s experimental new drug …Sanofi’s Lantus heir beats its forebear in controlling diabetesFierceBiotechSanofi’s Toujeo Drug Shows Promise as Lantus SuccessorBusinessweekSanofi, Medtronic Form Diabetes AllianceWall Street JournalMarketWatch -Livemint -Washington Postall 40 news articles …Read Full Story
New rivals to top diabetes drug Lantus show promise in studies - Reuters
Real Estate of Cebu
